Sovereign Financial Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Sovereign Financial Group’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5	Closed	-$3.68K	–	255
2023 Q3	$3.68K	Sell	5 -11	-69%	-$47.2K	﹤0.01%	226
2023 Q2	$72K	Sell	16 -4	-20%	-$13.9K	0.02%	228
2023 Q1	$51.8K	Hold	20	–	–	0.02%	213
2022 Q4	$50.9K	Hold	20	–	–	0.02%	217
2022 Q3	$77K	Hold	20	–	–	0.03%	200
2022 Q2	$51K	Hold	20	–	–	0.02%	208
2022 Q1	$63K	Buy	+20	New	+$86K	0.02%	215
2021 Q4	–	Sell	-5	Closed	-$48K	–	220
2021 Q3	$48K	Buy	+5	New	+$43K	0.03%	167

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sovereign Financial Group's SEEL Position: Q4 2023 in Review

Sovereign Financial Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 5 shares — an estimated $3.68K sold.

Sovereign Financial Group first reported a position in SEEL in Q3 2021 and held it in 8 quarters. The position peaked at $77K in Q3 2022. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Sovereign Financial Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Sovereign Financial Group sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.68K.
Sovereign Financial Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Sovereign Financial Group's Seelos Therapeutics, Inc. Common Stock position peaked at $77K in Q3 2022.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Sovereign Financial Group's 13F filing for Q4 2023, filed 6 Feb 2024.